GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Disc Medicine Inc (NAS:IRON) » Definitions » EV-to-FCF

IRON (Disc Medicine) EV-to-FCF : -18.08 (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Disc Medicine EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Disc Medicine's Enterprise Value is $1,522.18 Mil. Disc Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-84.21 Mil. Therefore, Disc Medicine's EV-to-FCF for today is -18.08.

The historical rank and industry rank for Disc Medicine's EV-to-FCF or its related term are showing as below:

IRON' s EV-to-FCF Range Over the Past 10 Years
Min: -22.19   Med: 0   Max: 2.16
Current: -18.08

During the past 4 years, the highest EV-to-FCF of Disc Medicine was 2.16. The lowest was -22.19. And the median was 0.00.

IRON's EV-to-FCF is ranked worse than
100% of 386 companies
in the Biotechnology industry
Industry Median: 8.605 vs IRON: -18.08

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-11), Disc Medicine's stock price is $65.93. Disc Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.980. Therefore, Disc Medicine's PE Ratio (TTM) for today is At Loss.


Disc Medicine EV-to-FCF Historical Data

The historical data trend for Disc Medicine's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Disc Medicine EV-to-FCF Chart

Disc Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -1.43 -3.61 -14.26

Disc Medicine Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.70 -14.26 -16.69 -11.29 -11.59

Competitive Comparison of Disc Medicine's EV-to-FCF

For the Biotechnology subindustry, Disc Medicine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Disc Medicine's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Disc Medicine's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Disc Medicine's EV-to-FCF falls into.



Disc Medicine EV-to-FCF Calculation

Disc Medicine's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1522.179/-84.208
=-18.08

Disc Medicine's current Enterprise Value is $1,522.18 Mil.
Disc Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Disc Medicine  (NAS:IRON) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Disc Medicine's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=65.93/-3.980
=At Loss

Disc Medicine's share price for today is $65.93.
Disc Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.980.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Disc Medicine EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Disc Medicine's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Disc Medicine Business Description

Traded in Other Exchanges
N/A
Address
321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
Executives
William Richard White director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
William Jacob Savage officer: Chief Medical Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kevin Bitterman director C/O POLARIS VENTURE PARTNERS, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Mona Ashiya director, 10 percent owner C/O SIERRA ONCOLOGY, INC., 2150 - 885 WEST GEORGIA STREET, VANCOUVER, BRITISH COLUMBIA Z4 V6C 3E8
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Joanne Bryce officer: Chief Financial Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Rahul Khara officer: General Counsel C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Brian Richard Macdonald officer: Chief Innovation Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Ai Dmi Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Atlas Venture Associates Opportunity I, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, Llc 10 percent owner 400 TECH. SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019